News Network


Post Conference Perspectives: Trilaciclib, a New Option for Chemotherapy-Induced Myelosuppression

May 6th 2021

Ralph Boccia, MD and Jim Schwartz, RPh provide key insights into the recent FDA approval of trilaciclib and discuss its impact on the treatment landscape for extensive-stage small cell lung cancer.

The Next Steps for CAR T-Cell Therapy in DLBCL

April 27th 2021

Amit Patel, BSc, MBBS, PhD, reviews key takeaways from the 2021 European Society for Blood and Marrow Transplantation symposium regarding the use of CAR T-cell therapy for patients with relapsed/refractory diffuse large B-cell lymphoma.

Exciting Approval in Europe for HER2-Positive Breast Cancer

April 7th 2021

Post-Conference Perspectives: ASCO GU 2021

March 8th 2021

The Role of Circulating Tumor (ct)DNA Testing/Monitoring in Stage II-III Colorectal Cancer

February 15th 2021

ASCO GU 2021 News

February 12th 2021

Chemotherapy-Free Intervals in Management of Metastatic Colorectal Cancer

January 22nd 2021

The Role and Rationale for Oral Options in the Treatment of Metastatic Breast Cancer

January 19th 2021

ASCO GI 2021 News

January 16th 2021

OncLive® will be LIVE with OncLive® News Network: On Location at the virtual 2021 ASCO GI. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented in gastrointestinal cancer during the virtual conference.

Treatment Options in Triple-Class Refractory Multiple Myeloma

January 14th 2021

First-Line Extensive-Stage SCLC: Examining the New Role of Combination Chemotherapy and Immunotherapy

December 11th 2020

SABCS 2020 News

December 9th 2020

OncLive will be LIVE with OncLive News Network: On Location at the virtual 2020 San Antonio Breast Cancer Symposium. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented in breast cancer during the virtual conference.

ASH 2020 News

December 3rd 2020

OncLive will be LIVE with OncLive News Network: On Location at the virtual 2020 ASH Annual Meeting. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented during the virtual conference.

Back to the Future: How New and Emerging Trends in CAR T-Cell Therapy Can Affect Your Patients

October 16th 2020

Managing High-Dose Methotrexate Toxicity

October 1st 2020

New Fixed-Dose Subcutaneous Option for HER2+ Breast Cancer

September 24th 2020

A New Chapter in DLBCL: Uncovering New Treatment Options For Your Patients

September 22nd 2020

ESMO 2020 News

September 19th 2020

Today-

We are reporting from the 2020 ESMO Virtual Congress!

We are recapping some of the top news that are being presented during the conference—and in just a bit we’ll be speaking with Dr Robert Coleman to get his take on the biggest abstracts in gynecologic cancers, and also with Dr Shilpa Gupta on the latest in genitourinary cancers.

Welcome to OncLive News Network! I’m Gina Mauro.

In renal cell carcinoma, results of the phase 3 CheckMate-9ER trial showed that the combination of nivolumab and cabozantinib was found to double progression-free survival and objective response rates, and also significantly improve overall survival, compared with sunitinib, in patients with advanced disease who have not received prior treatment.

In basal cell carcinoma, the PD-1 antibody cemiplimab established encouraging clinical activity in patients with locally advanced disease who progress on or are intolerant to hedgehog inhibitors, regardless of PD-L1 expression, according to primary cohort results of a phase 2 trial presented during the meeting.

In an interim analysis of a subset of patients with intrahepatic cholangiocarcinoma harboring FGFR2 fusions/rearrangements, the oral small molecule inhibitor futibatinib was shown to be efficacious and tolerable. Investigators recorded a 37.3% objective response rate in the analysis of 67 patients with at least 6 months of follow-up. One patient had complete response and 24 patients had partial response.

Findings from the phase 3 IPATunity trial showed that the combination of ipatasertib plus paclitaxel did not improve efficacy in patients with PIK3CA/AKT1/PTEN-altered hormone receptor–positive advanced breast cancer. However, follow-up for overall survival is ongoing.

A subgroup analysis from the phase 3 JAVELIN Bladder 100 trial demonstrated that frontline maintenance therapy with avelumab plus best supportive care provided an overall survival benefit compared with best supportive care alone across prespecified subgroups of patients whose disease had not progressed with frontline induction chemotherapy. Avelumab was approved by the FDA earlier in 2020 for this indication.

Two phase 2 trials in cervical cancer showcased activity with the PD-1 inhibitor balstilimab in patients with recurrent/metastatic disease. As a single agent, he response rate was 14% of all patients with the disease 19% in PD-L1–positive patients. For patients who received balstilimab plus the CTLA-4 inhibitor zalifrelimab, the ORRs were 22% and 27% in PD-L1–positive patients with recurrent/metastatic cervical cancer, respectively.

A first-in-human trial showed that the novel FAP-targeted 4-1BB agonist RO7122290 demonstrated an acceptable safety profile as a single agent and in combination with atezolizumab. Moreover, there were favorable pharmacokinetic and pharmacodynamic effects, and the preliminary antitumor activity supports further investigation in clinical trials.

For more coverage of the 2020 ESMO Virtual Congress, please be sure to visit onclive.com.

That’s all for today. Tomorrow on OncLive News Network: On Location, we’ll speak with Dr Scott Tagawa to get perspectives on other studies being presentted in genitourinary cancers, and Dr Stephen Liu to get the latest ESMO abstracts in lung cancer.

Thank you for watching OncLive News Network! I’m Gina Mauro. 

Which of the following stories from the 2020 ESMO Virtual Congress did you find most exciting?

Current and Future Directions in Metastatic Pancreatic Cancer

September 1st 2020

Speaker
Thomas A. Abrams, MD

Medical Oncologist
Dana-Farber Cancer Institute

Sponsored by:

Recent Advances in Small-Cell Lung Cancer

August 20th 2020